Barry Paul, MD, on Managing CRS and ICANS in Patients Receiving CAR-T for Cancer

Video

Paul discussed common symptoms and typical treatments for the 2 adverse events.

This content originally appeared on our sister site, OncLive.

Two adverse events (AEs) associated with chimeric antigen receptor T-cell (CAR-T) therapies are cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).

In an interview with OncLive, Barry Paul, MD, assistant professor, the Division of Plasma Cell Disorders, the Department of Hematologic Oncology and Blood Disorders, Atrium Health, discussed the symptoms of these adverse events and how they are typically treated in patients receiving CAR-T for the treatment of cancer.

Paul pointed out that CRS is a systemic inflammatory response which is secondary to the activation of bystander immune and non-immune cells. He explained that the activation of these cells leads to significant increase in interleukin-1 (IL-1) and IL-6, which leads to fever, fatigue, headaches, arthralgias, and myalgias. Paul also noted that more severe cases of CRS can present with hypotension, shock, or multi-system organ failure and mentioned that the syndrome can be managed with tocilizumab (Actemra) if supportive care via antipyretics, acetaminophen, supplemental oxygen, and intravenous fluids is not effective.

Paul also discussed ICANS, highlighting the fact that it occurs when cytokines penetrate the central nervous system (CNS). He explained that ICANs may present with more CNS symptoms, including headache, confusion, and impaired motor skills, and noted that more severe cases may involve aphasia, seizures, cerebral edema, or coma. Paul concluded by mentioning that because tocilizumab is ineffective due to its inability to cross the blood-brain barrier, high-dose corticosteroids are used to treat patients experiencing ICANS.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.